HAS
37
3
WYNN
42
4
PRGO
40
-3
AVY
57
2
MAC
65
-3
SCHW
65
-2
PFE
28
2
WU
32
-2
MA
67
2
NWS
60
2
L
65
-3
BLK
55
-2
CCI
36
-2
ES
29
-12
LB
49
-14
SLB
56
3
AA
61
5
DG
29
19
HCA
48
2
CMG
69
-3
HAS
37
3
WYNN
42
4
PRGO
40
-3
AVY
57
2
MAC
65
-3
SCHW
65
-2
PFE
28
2
WU
32
-2
MA
67
2
NWS
60
2
L
65
-3
BLK
55
-2
CCI
36
-2
ES
29
-12
LB
49
-14
SLB
56
3
AA
61
5
DG
29
19
HCA
48
2
CMG
69
-3
Financhill
Back

Verrica Pharmaceuticals Quote, Financials, Valuation and Earnings

Sell
50

VRCA
Verrica Pharmaceuticals

Last Price:
1.28
Seasonality Move:
40.31%

7 Day Trial

ALL ACCESS PASS

$ 7

Verrica Pharmaceuticals Price Quote

$1.28

Verrica Pharmaceuticals Key Stats

Sell
50
Verrica Pharmaceuticals (VRCA) is a Sell
Day range:
$1.11 - $1.30
52-week range:
$0.70 - $11.41
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.47
P/B ratio:
0%
Volume:
636.2K
Avg. volume:
811.2K
1-year change:
-67.26%
Market cap:
$115.9M
Revenue:
$5.1M
EPS:
$-1.84

How Much Does Verrica Pharmaceuticals Make?

Is Verrica Pharmaceuticals Growing As A Company?

Data Unavailable

Verrica Pharmaceuticals Stock Price Performance

What Is Verrica Pharmaceuticals 52-Week High & Low?

Verrica Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Verrica Pharmaceuticals?

Is Verrica Pharmaceuticals Cash Flow Positive?

  • What Is VRCA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$59.4M
  • What Is Verrica Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$1.7M
  • What Is Verrica Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$254K

Verrica Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    VRCA return on invested capital is -184.44%
  • What Is Verrica Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -128.78%
  • What Is VRCA Return On Equity?
    ROE is a measure of profitability and is -2619.46%

Verrica Pharmaceuticals Earnings Date & Stock Price

Verrica Pharmaceuticals Competitors

Verrica Pharmaceuticals Dividend Yield

Verrica Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -26.45%
Revenue: 0% -133.85%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 6.33
Upside from Last Price: 394.79%

Major Shareholders

  • How many VRCA shares are owned by institutional investors?
    22.9M VRCA shares are owned by institutional investors
  • How many VRCA shares are owned by insiders?
    11.7M VRCA shares are owned by insiders